Slides - Page 3 of 11 - Cancer Therapy Advisor

Slides

ELITEK (rasburicase) for Initial Management of Plasma Uric Acid Levels

This slideshow reviews drug information for ELITEK (rasburicase), indicated for initial management of plasma uric acid levels.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 6: Use in Specific PopulationsSlide 8: Clinical PharmacologySlide 12: Warnings and PrecautionsSlide 16: Clinical Safety and EfficacySlide 22: Drug Storage and SupplySlide 24: References

MOZOBIL (plerixafor) for Non-Hodgkin’s Lymphoma and Multiple Myeloma

This slideshow reviews drug information for MOZOBIL (plerixafor), indicated for Non-Hodgkin’s lymphoma andmultiple myeloma.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical PharmacologySlide 13: Warnings and PrecautionsSlide 17: Clinical Safety and EfficacySlide 23: Drug Storage and SupplySlide 25: References

JEVTANA (cabazitaxel) for Metastatic Prostate Cancer

This slideshow reviews drug information for JEVTANA (cabazitaxel), indicated for metastatic prostate cancer.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical PharmacologySlide 13: Warnings and PrecautionsSlide 17: Clinical Safety and EfficacySlide 23: Drug Storage and SupplySlide 25: References

FARYDAK (panobinostat) for Relapsed Multiple Myeloma

This slideshow reviews drug information for FARYDAK (panobinostat), indicated for relapsed multiple myeloma.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 25: Drug Storage and SupplySlide 27: References

OPDIVO (nivolumab) for Unresectable or Metastatic Melanoma

This slideshow reviews drug information for OPDIVO (nivolumab), indicated for unresectable or metastatic melanoma.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 14: Warnings and PrecautionsSlide 18: Clinical Safety and EfficacySlide 23: Drug Storage and SupplySlide 25: References

LENVIMA (lenvatinib) for Thyroid Cancer

This slideshow reviews drug information for LENVIMA (lenvatinib), indicated for thyroid cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 20: Clinical Safety and EfficacySlide 26: Drug Storage and SupplySlide 28: References

GLEEVEC (imatinib) for Ph+ Chronic Myeloid Leukemia

This slideshow reviews drug information for GLEEVEC (imatinib), indicated for Ph+ chronic myeloid leukemia.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 12: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 30: Drug Storage and SupplySlide 32: References

CYRAMZA (ramucirumab) for Metastatic Colorectal Cancer

This slideshow reviews drug information for CYRAMZA (ramucirumab), indicated for metastatic colorectal cancer.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 14: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 24: Drug Storage and SupplySlide 26: References

BLINCYTO (blinatumomab) for B-Cell Precursor Acute Lymphoblastic Lymphoma

This slideshow reviews drug information for BLINCYTO (blinatumomab), indicated for B-cell precursor acute lymphoblastic lymphoma.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 14: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 25: Drug Storage and SupplySlide 27: References

Next hm-slideshow in Slides